
    
      The management of critical limb ischemia due to below-the-knee disease remains challenging
      due to the frequent patient comorbidities, diffuse vascular involvement, limb preservation,
      and high rates of restenosis and disease progression. This study will record the use of
      ELUTAX SV-DEB under real life conditions in a representative sample.The investigators will
      generate new data in observing the outcome and the safety of the Elutax SV drug-eluting
      balloons for change in Rutherford clinical category from baseline to 6 and 12 month follow-up
      visits.
    
  